RAPT Therapeutics Net Worth
RAPT Therapeutics Net Worth Breakdown | RAPT |
RAPT Therapeutics Net Worth Analysis
RAPT Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including RAPT Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of RAPT Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform RAPT Therapeutics' net worth analysis. One common approach is to calculate RAPT Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares RAPT Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing RAPT Therapeutics' net worth. This approach calculates the present value of RAPT Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of RAPT Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate RAPT Therapeutics' net worth. This involves comparing RAPT Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into RAPT Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if RAPT Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding RAPT Therapeutics' net worth research are outlined below:
| RAPT Therapeutics generated a negative expected return over the last 90 days | |
| RAPT Therapeutics has high historical volatility and very poor performance | |
| RAPT Therapeutics has some characteristics of a very speculative penny stock | |
| RAPT Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (116.8 M) with profit before overhead, payroll, taxes, and interest of 1.53 M. | |
| RAPT Therapeutics currently holds about 207.34 M in cash with (97.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: RAPT Therapeutics Analysts Recent Ratings Changes |
RAPT Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in RAPT Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to RAPT Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know RAPT Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as RAPT Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading RAPT Therapeutics backward and forwards among themselves. RAPT Therapeutics' institutional investor refers to the entity that pools money to purchase RAPT Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 683.2 K | State Street Corp | 2024-06-30 | 671.8 K | Euclidean Capital Llc | 2024-09-30 | 657.9 K | Alphabet Inc | 2024-09-30 | 540.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 525.2 K | Two Sigma Investments Llc | 2024-09-30 | 520.4 K | Redmile Group, Llc | 2024-09-30 | 504.5 K | Cormorant Asset Management, Llc | 2024-09-30 | 496.8 K | Goldman Sachs Group Inc | 2024-06-30 | 373.8 K | Fmr Inc | 2024-09-30 | 5.2 M | Vanguard Group Inc | 2024-09-30 | 3.2 M |
Follow RAPT Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.75 M.Market Cap |
|
Project RAPT Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.71) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.67) | (0.71) | |
| Return On Equity | (0.79) | (0.83) |
When accessing RAPT Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures RAPT Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of RAPT Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in RAPT Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RAPT Therapeutics. Check RAPT Therapeutics' Beneish M Score to see the likelihood of RAPT Therapeutics' management manipulating its earnings.
Evaluate RAPT Therapeutics' management efficiency
RAPT Therapeutics has return on total asset (ROA) of (0.4658) % which means that it has lost $0.4658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8013) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.71 in 2024. Return On Capital Employed is likely to drop to -0.88 in 2024. Total Current Liabilities is likely to drop to about 11.7 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 151.1 M in 2024| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.84 | 2.88 | |
| Tangible Book Value Per Share | 3.84 | 2.88 | |
| Enterprise Value Over EBITDA | (7.25) | (7.61) | |
| Price Book Value Ratio | 6.48 | 6.80 | |
| Enterprise Value Multiple | (7.25) | (7.61) | |
| Price Fair Value | 6.48 | 6.80 | |
| Enterprise Value | 883.8 M | 522.4 M |
Effective leadership at RAPT Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 677.3673 | Quarterly Revenue Growth (1.00) | Return On Equity (0.80) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RAPT Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on RAPT Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RAPT Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RAPT Therapeutics time-series forecasting models is one of many RAPT Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary RAPT Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
RAPT Therapeutics Earnings per Share Projection vs Actual
RAPT Therapeutics Corporate Management
| Gwen Carscadden | Chief Officer | Profile | |
| Rodney Young | Principal CFO | Profile | |
| David Wustrow | Senior Development | Profile | |
| William Ho | Chief Officer | Profile | |
| Jennifer Nicholson | Senior Assurance | Profile | |
| Michael Listgarten | General Counsel | Profile | |
| William MD | Chief Officer | Profile |
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.